Third Rock Ventures, LLC.
SEC exempt reporting adviser (venture capital exemption).
- HQ
- MA
Third Rock Ventures is a biotechnology venture capital firm that builds biotech companies aiming to discover and develop products that make a difference for patients. Its portfolio includes companies with recent news such as Revolution Medicines, Otarmeni, Aqvesme, Marea Therapeutics, Merida Biosciences, Candid Therapeutics, Tango Therapeutics, insitro, Rapport Therapeutics, and Seaport Therapeutics. The firm also announced a new team member, Sarah DeVos.
01 · Says / Does
| Tag | Says | Does | Historically (to 2020) |
|---|---|---|---|
| Stages | Seed | Not enough dated deals | Series A, Series B, Growth |
| Sectors | Biotech | Not enough dated deals | Biotech, Healthtech, Medical devices, Life sciences and research tools |
| Regions | US | Not enough dated deals | MA, CA |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
Historical focus (through 2020), derived from historical deal data.
| Year | Deals | Top sectors |
|---|---|---|
| 2008 | 2 | Biotech, Healthtech |
| 2009 | 2 | Biotech, Healthtech |
| 2010 | 9 | Healthtech, Biotech, Medical devices |
| 2011 | 14 | Biotech, Healthtech, Medical devices |
| 2012 | 15 | Biotech, Healthtech, Medical devices |
| 2013 | 9 | Biotech, Healthtech, Medical devices |
| 2014 | 12 | Biotech, Healthtech, Life sciences and research tools |
| 2015 | 8 | Biotech, Healthtech, Life sciences and research tools |
| 2016 | 8 | Healthtech, Biotech, Medical devices |
| 2017 | 7 | Biotech, Healthtech, Life sciences and research tools |
| 2018 | 9 | Biotech, Healthtech, Life sciences and research tools |
| 2019 | 4 | Biotech, Healthtech, Life sciences and research tools |
| 2020 | 4 | Biotech, Healthtech, Life sciences and research tools |
Stage mix over time
- Pre-seed
- Seed
- Series A
- Series B
- Growth
| Year | Pre-seed | Seed | Series A | Series B | Growth |
|---|---|---|---|---|---|
| 2010 | 0 | 1 | 4 | 4 | 0 |
| 2011 | 0 | 0 | 8 | 3 | 3 |
| 2012 | 0 | 1 | 5 | 4 | 5 |
| 2013 | 0 | 1 | 3 | 2 | 1 |
| 2014 | 0 | 0 | 2 | 6 | 3 |
| 2015 | 0 | 0 | 4 | 1 | 3 |
| 2016 | 0 | 0 | 6 | 2 | 0 |
| 2017 | 0 | 0 | 1 | 4 | 1 |
| 2018 | 0 | 0 | 6 | 1 | 2 |
| 2019 | 0 | 0 | 3 | 0 | 1 |
| 2020 | 0 | 0 | 1 | 1 | 1 |
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2022 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 0 |
| 2026 | 0 | 0 | 0 | 0 | 0 |
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| Third Rock Ventures VII, L.P. Third Rock Ventures is a biotechnology venture capital firm that builds companies from scientific discovery, starting at the seed stage. It focuses on medicines that address unmet medical need and aims to bring breakthrough products to patients. Inferred from the firm's website | approx. 2026 | $750M (Form D) | Raising |
| Third Rock Ventures VI, L.P. Third Rock Ventures is a biotechnology venture capital firm that builds companies from scientific discovery, starting at the seed stage. It focuses on medicines that address unmet medical need and aims to bring breakthrough products to patients. Inferred from the firm's website | 2022 | $1105.34M to $1111.09M (Form D and SEC adviser filing) | Late investment period |
03 · People across funds
- Abbie Celniker, Manager of the GPLLC.
Third Rock Ventures VI, L.P. (Named on Form D)
- Andrea van Elsas, Manager of the GPLLC.
Third Rock Ventures VII, L.P. (Named on Form D)
- Cary Pfeffer, Manager of the GPLLC.
Third Rock Ventures VI, L.P. (Named on Form D)
- David Kaufman, Manager of the GPLLC.
Third Rock Ventures VI, L.P. (Named on Form D)
- Jeffrey Tong, Manager of the GPLLC.
Third Rock Ventures VII, L.P. (Named on Form D); Third Rock Ventures VI, L.P. (Named on Form D)
- Jigar Raythatha, Manager of the GPLLC.
Third Rock Ventures VII, L.P. (Named on Form D)
- Kevin Gillis, Manager of the GPLLC.
Third Rock Ventures VII, L.P. (Named on Form D); Third Rock Ventures VI, L.P. (Named on Form D)
- Neil Exter, Manager of the GPLLC.
Third Rock Ventures VI, L.P. (Named on Form D)
- Reid Huber, Manager of the GPLLC.
Third Rock Ventures VII, L.P. (Named on Form D); Third Rock Ventures VI, L.P. (Named on Form D)
- Robert Tepper, Manager of the GPLLC.
Third Rock Ventures VI, L.P. (Named on Form D)
- Sarah DeVos
Third Rock Ventures VII, L.P. (Team); Third Rock Ventures VI, L.P. (Team)
- Andrea van Elsas, Ph.D., Partner
On the team page, not linked to a fund
- Christoph Lengauer, Ph.D., Partner
On the team page, not linked to a fund
- David Kaufman, M.D., Ph.D., Partner
On the team page, not linked to a fund
- Jeffrey Tong, Ph.D., Partner
On the team page, not linked to a fund
- Phil Reilly, Venture Partner
On the team page, not linked to a fund
- Reid Huber, Ph.D., Partner
On the team page, not linked to a fund
- Sarah DeVos, PhD
On the team page, not linked to a fund
- Sarah Larson, Partner
On the team page, not linked to a fund
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
- HTTP://WWW.THIRDROCKVENTURES.COM
- https://www.thirdrockventures.com/media-center
- https://www.thirdrockventures.com/
- https://www.thirdrockventures.com/approach
- https://www.thirdrockventures.com/people
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 28, 2026